Skip to main content
Clinical Trials/NCT03077867
NCT03077867
Completed
Not Applicable

Comparison of Histological and Radiographic Evidence After Sinus Lift With Synthetic Nano-hydroxyapatite and Inorganic Bovine Bone.

International Piezosurgery Academy1 site in 1 country88 target enrollmentJanuary 15, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alveolar Bone Loss
Sponsor
International Piezosurgery Academy
Enrollment
88
Locations
1
Primary Endpoint
comparison of histological performance of the bone grafts
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This is set as prospective clinical trial to correlate histologically and radiologically the performance of four different bone grafts (synthetic hydroxyapatite alone, synthetic hydroxyapatite mixed with polylactic-polyglycolic acid, synthetic hydroxyapatite with i-PRF and inorganic bone graft) in the sinus floor elevation technique with lateral approach for the treatment of atrophic crests.

Detailed Description

SURGICAL PROCEDURE: After local anesthesia and a large full-thickness mucoperiosteal flap in the area of interest, an osteotomy window on the side wall of the maxillary sinus will be opened using bone scrapers and / or ultrasonic instruments. Will be recorded the time needed for the opening dell'antrostomy and any perforations of the membrane at this stage. The Schneider membrane is then gently elevated with ultrasonic instrumentation and curettes manuals: after testing the integrity of the membrane by means of visual inspection and the Valsalva maneuver, the sealed envelope in which will be indicated to the surgeon the material to be used as a graft will be opened. The biomaterials selected for this study are a synthetic nano-hydroxyapatite (SNHA) (FISIOGRAFT Bone, Italy), to be used either alone, or mixed with a polylactic- polyglycolic copolymer (PLGA) (FISIOGRAFT, Italy), or mixed with autologous platelet derived (i-PRF) and inorganic bovine bone (ABB) (Bio-Oss, Geistlich, Switzerland). After completing the insertion of the biomaterial, the antrostomy will be protected with a resorbable collagen membrane (BioGide, Geistlich, Switzerland) and the flaps will be sutured with a synthetic monofilament. It will prescribe antibiotics for 6 days (amoxicillin 1 g twice daily or, in allergic patients, clarithromycin 250 mg twice a day) and NSAIDs (ibuprofen 600 mg), as needed. An aerosol treatment with beclomethasone dipropionate and n-acetylcysteine (Fluimucil, Zambon, Italy) will be prescribed at the discretion of the clinician. POSTOPERATIVE RECALLS: The sutures will be removed after 10 days and a cone beam computed tomography X-ray will be performed to assess the correct distribution of the graft material and early intercept any accidental leakage of the same in the sinus cavities. After six months it will proceed to a new radiographic evaluation to assess the resulting regeneration and be able to plan the implant placement. It will then proceed to the preparation of the sites for the implants using twist-drills. The fixtures are left healed submerged for a period of four months, at the end of which will be connected with the healing screws to start the prosthetic procedures. After therapy patients will enter a maintenance program with periodic reminders of professional oral hygiene. Patients will be re-evaluated clinically and radiologically after one, three and five years to control the condition of the plants and the stability of the performed regeneration.

Registry
clinicaltrials.gov
Start Date
January 15, 2017
End Date
March 15, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
International Piezosurgery Academy
Responsible Party
Principal Investigator
Principal Investigator

Mr. Claudio Stacchi, DDS, MSc

President of the International Piezosurgery Academy

International Piezosurgery Academy

Eligibility Criteria

Inclusion Criteria

  • indications for intervention of sinus lift with lateral approach to allow the insertion of dental implants, based on careful diagnosis and treatment plan;
  • presence of residual bone crest with a height ≤3 mm on the maxillary sinus, at the level of the implant sites planned;
  • the bone crest must be intact (at least 3 months after the loss / extraction of the element corresponding tooth);
  • patients must be able to examine and understand the study protocol; 6) informed consent.

Exclusion Criteria

  • acute myocardial infarction within the last six months;
  • uncontrolled bleeding disorders;
  • uncontrolled diabetes (HBA1c\> 7.5%);
  • radiation therapy in the district head / neck in the last 24 months;
  • immunocompromised (e.g. HIV infection or chemotherapy in the last three years);
  • current or past treatment with intravenous bisphosphonates;
  • allergy to bovine collagen;
  • psychological or psychiatric diseases;
  • abuse of alcohol or drug use;
  • not controlled periodontal disease;

Outcomes

Primary Outcomes

comparison of histological performance of the bone grafts

Time Frame: 6 months after surgery

histomorphometric analysis

Secondary Outcomes

  • comparison of radiological evidence of the bone grafts(before surgery and 6 months after surgery)
  • implant success(6 months after surgery)

Study Sites (1)

Loading locations...

Similar Trials